Medical News

RSS

Scientists to develop new MR imaging techniques for brain study

A Norwegian research centre is developing new magnetic resonance imaging techniques to study the brain. This could have impact for victims of brain damage as well as Alzheimer patients.

19 Mar 2011

Researchers identify protein that triggers immune response in TB-infected people

Scientists have discovered a protein secreted by tuberculosis bacteria that could be a promising new vaccine candidate, they report today in Proceedings of the National Academy of Sciences. The protein could also be used to improve diagnosis of TB.

19 Mar 2011

Researchers discover process that regulates DNA maintenance

DNA contains all of the genetic instructions that make us who we are, and maintaining the integrity of our DNA over the course of a lifetime is a critical, yet complex part of the aging process.

19 Mar 2011

BD acquires Accuri Cytometers

BD, a leading global technology company, today announced the completion of its acquisition of Accuri Cytometers, Inc., an Ann Arbor, Michigan-based company that develops and manufactures personal flow cytometers for researchers.

From BD (Becton, Dickinson and Company) 19 Mar 2011

Tocopherol derivatives as new dioxin receptor antagonists

When reactive oxygen species (ROS) hit the body, vitamin E helps to prevent damage to tissues and cells by acting as an antioxidant. The health benefits of vitamin E are numerous, and in fact, studies have found that people with higher levels of vitamin E in their system have a lower risk of heart disease and certain forms of cancer. A team led by Thomas Rosenau from the University of Natural Resources and Life Sciences in Vienna (Austria) now describe their synthesis of a series of modified vitamin E derivatives that show promise as dioxin receptor antagonists in the European Journal of Organic Chemistry.

18 Mar 2011

Cancer Care Partners first in U.S. to use new, advanced cancer treatment

On March 7, 2010, Cancer Care Partners became the first cancer center in the United States to use the new TomotherapyHD, a comprehensive, image guided radiation therapy system that enables Cancer Care Partners to more efficiently treat complex tumors with improved precision.

18 Mar 2011

NovaSterilis awarded NIH funding for supercritical CO2 sterilization of advanced biomaterials and absorbable sutures

NovaSterilis today received a $100,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for developing a supercritical CO2 process to sterilize absorbable sutures and advanced biomaterials. The grant funds a collaboration with Chih-Chang Chu Ph.D, a pioneer in absorbable polymer development at Cornell University.

18 Mar 2011

Commentary on the global challenges of emerging viral infections

Paul Duprex, PhD, and Elke Mühlberger, PhD, both associate professors of microbiology at Boston University School of Medicine (BUSM), recently co-authored a commentary about viruses for Microbiology Today, the monthly publication of the Society of General Microbiology, which is the largest microbiological society in Europe. The article focuses on the history of viruses and vaccines and gives their perspective on what is necessary to evolve to the next era of virology research.

18 Mar 2011

[UPDATE] Pediatric heart surgery unit of Royal Brompton faces closure

A London NHS trust would challenge proposals to end child heart surgery at the Royal Brompton Hospital. The Royal Brompton and Harefield NHS Foundation Trust added that this would mean the loss of other services, which could call into question its viability.

18 Mar 2011

Olympus offers new stones retrieval products

Over the last years, the equipment for endoscopy and training of ureteroscopy has improved significantly. The shift from ESWL to ureteroscopy is evident.

From Evident Corporation - Life Sciences 18 Mar 2011

Scant high-quality research on hospice care in nursing homes

A new evidence review finds that there's scant high-quality research on the best comprehensive strategies for nursing homes hoping to ease the suffering of older patients through hospice care.

18 Mar 2011

RainDance Technologies launches ASDSeq and XSeq Research Screening Panels

RainDance Technologies, Inc., today announced the commercial availability of the ASDSeq™ and XSeq™ Research Screening Panels. Developed in collaboration with Emory University and Greenwood Genetic Center, the two comprehensive panels enable researchers to simultaneously interrogate key genes known to be linked to X-chromosome disorders and syndromic forms of Autism Spectrum Disorder (ASD) using next-generation sequencing.

18 Mar 2011

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

18 Mar 2011

Sage Bionetworks, AstraZeneca enter cancer research collaboration

Sage Bionetworks and AstraZeneca have initiated a collaboration to make new insights into certain cancers using advanced computational models of disease genetics. This deeper understanding of cancer will potentially help better match patients with appropriate treatments and might one day lead to new cancer therapeutics.

18 Mar 2011

Aerocrine acquires FENO technology platform and intellectual property from FILT

Aerocrine AB today announced the acquisition of key assets related to the measurement of FENO from German company FILT Lungen & Thoraxdiagnostik GmbH. FILT and Aerocrine will collaborate to develop new applications for airway inflammation monitoring and FILT will cease further commercialization of the NO VARIO® product.

18 Mar 2011

EMA CHMP adopts positive opinion for Teva's NOMAC-E2 contraceptive pill

Teva Pharmaceutical Industries Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NOMAC-E2, an investigational contraceptive pill combining 1.5 mg of 17-beta-estradiol with 2.5 mg of nomegestrol acetate in a 24/4 monophasic regimen.

18 Mar 2011

PixelOptics launches world's first electronically-focusing prescription eyewear

Following an award-winning preview at the Consumer Electronics Show in Las Vegas, PixelOptics today announced the formal introduction of emPower!, the world's first electronically-focusing prescription eyewear, at Vision Expo East in New York this week.

18 Mar 2011

Affymax prices underwritten public offering of common stock

Affymax, Inc., today announced the pricing of an underwritten public offering of 8,474,576 shares of its common stock at a price to the public of $5.90 per share. The gross proceeds to Affymax from this offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

18 Mar 2011

Medical expert offers tips to protect from nuclear radiation exposure

As the world watches the nuclear tragedies unfold in Japan, fears are rising regarding the potential for radioactive fallout to travel to the United States, particularly the West Coast. Could this really happen and can we protect ourselves from a nuclear event? The general answer to both questions is yes, according to Medical Expert Dr. Isaac Eliaz.

18 Mar 2011

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

From Quest Diagnostics 18 Mar 2011